Mazen Animal Health
Mazen’s novel vaccine platform uses maize as a biofactory for the production of recombinant vaccines. This unique approach enables oral delivery of vaccines in an edible form with distinct advantages over today’s injectables, topicals and water-based orals. The cross-species platform has the flexibility to be used in swine, poultry, livestock, aquaculture, pets and wildlife, and has the potential for vaccine solutions for a wide variety of diseases. It has the potential to expand the $5 billion global vaccine market while dramatically reducing losses. Mazen is led by the founders and supported by a group of advisors with expertise in animal health, regulatory, manufacturing, marketing and growing businesses.